Merck Inks Up to $4.5 Billion Seattle Genetics Cancer Deal

(Bloomberg) -- Merck & Co. plans to take an equity stake and pay as much as $4.5 billion in a series of deals with Seattle Genetics Inc. for two of its cancer drugs.